Drug Profile
Retifanlimab - Incyte Corporation/MacroGenics
Alternative Names: AEX-1188; INCMGA-0012; INCMGA00012; MGA-012; Retifanlimab-dlwr; ZynyzLatest Information Update: 19 Mar 2024
Price :
$50
*
At a glance
- Originator MacroGenics
- Developer BriaCell Therapeutics Corp; Incyte Corporation; MacroGenics; University of Washington; ZAI Lab
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Merkel cell carcinoma
- Preregistration Squamous cell cancer
- Phase III Endometrial cancer; Non-small cell lung cancer
- Phase II/III Gastric cancer; Oesophageal cancer
- Phase II Adenosquamous carcinoma; Bladder cancer; Glioblastoma; Glioma; Head and neck cancer; Liposarcoma; Pancreatic cancer; Penile cancer; Sarcoma; Solid tumours; Triple negative breast cancer
- Phase I/II Breast cancer; Colorectal cancer; Malignant melanoma; Soft tissue sarcoma
- Phase I Adenocarcinoma
- No development reported Acute myeloid leukaemia; Haematological malignancies
Most Recent Events
- 08 Mar 2024 Retifanlimab is still in phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT04580485)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 22 Feb 2024 Incyte Corporation completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, France, Italy, Spain, United Kingdom and the US (IV) (NCT04580485)